Tuinal was introduced as a sedative medication in the late 1940s by Eli Lilly. It was produced in gelatin capsule form for oral administration. Individual capsules contained 50 mg, 100 mg, or 200 mg of barbiturate salts.
Eli Lilly has discontinued the manufacture of Tuinal in the United States due to the diminishing use of barbiturates in outpatient treatment. Currently Ranbaxy Pharmaceuticals is the sole producer of this barbiturate formulation. In the United Kingdom, Tuinal, Seconal and sodium amytal are manufactured by Flynn Pharma of Ireland. Amytal has been discontinued, though sodium amytal remains.